S. Poletajew, R. Biernacki, P. Buraczyński, J. Chojnacki, S. Czarniecki, D. Gajewska, T. Pohaba, J. Sondka, M. Skrzypczyk, T. Suchojad, D. Wojtkowiak, B. Zaforemski, Ł. Zapała, A. Zemła, P. Radziszewski
{"title":"Patterns of care in patients with muscle-invasive bladder cancer – a retrospective cohort study","authors":"S. Poletajew, R. Biernacki, P. Buraczyński, J. Chojnacki, S. Czarniecki, D. Gajewska, T. Pohaba, J. Sondka, M. Skrzypczyk, T. Suchojad, D. Wojtkowiak, B. Zaforemski, Ł. Zapała, A. Zemła, P. Radziszewski","doi":"10.5114/wo.2016.61857","DOIUrl":null,"url":null,"abstract":"A potential reason for poor survival among patients with muscle-invasive bladder cancer (MIBC) in Poland is initial disqualification from curative treatment due to advanced stage of the disease or low performance status. The aim of this study was to describe patterns of care in patients with newly diagnosed MIBC. This is a multicentre retrospective cohort study involving 296 consecutive patients with primary histologically diagnosed MIBC. Therapeutic decisions and potentially underlying clinical factors were analysed. Full clinical data was available for 285 patients. One hundred and sixty-four (57.5%) patients were qualified for radical cystectomy (RC), 32 (11.2%) patients for a second step of transurethral resection of the bladder tumour (TURBT) intentionally followed by systemic chemotherapy, four (1.4%) patients after complete TURBT were qualified for adjuvant intravesical chemotherapy only, while the remaining 85 (29.8%) patients were qualified for palliative treatment in the form of chemotherapy and/or radiotherapy and/or best supportive care. Patients disqualified from curative treatment were older (78 vs. 69 years, p < 0.02), had lower BMI values (24.5 vs. 25.7 kg/m2, p < 0.02), lower haemoglobin concentration (11.6 vs. 12.9 mg/l, p < 0.02), declared lower rate of nicotine abuse (50.5% vs. 72.1%, p < 0.02), and had a shorter time interval between first symptom and diagnosis (30 vs. 60 days, p = 0.02). As the majority of Polish patients with primary MIBC receive curative treatment, the stage of the disease alone seems not to be the leading cause of poor survival. However, appropriateness of qualification for RC and treatment quality needs to be assessed for final conclusion on the factors influencing outcomes of treatment in Poland.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"1 1","pages":"341 - 343"},"PeriodicalIF":0.0000,"publicationDate":"2016-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Contemporary Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/wo.2016.61857","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4
Abstract
A potential reason for poor survival among patients with muscle-invasive bladder cancer (MIBC) in Poland is initial disqualification from curative treatment due to advanced stage of the disease or low performance status. The aim of this study was to describe patterns of care in patients with newly diagnosed MIBC. This is a multicentre retrospective cohort study involving 296 consecutive patients with primary histologically diagnosed MIBC. Therapeutic decisions and potentially underlying clinical factors were analysed. Full clinical data was available for 285 patients. One hundred and sixty-four (57.5%) patients were qualified for radical cystectomy (RC), 32 (11.2%) patients for a second step of transurethral resection of the bladder tumour (TURBT) intentionally followed by systemic chemotherapy, four (1.4%) patients after complete TURBT were qualified for adjuvant intravesical chemotherapy only, while the remaining 85 (29.8%) patients were qualified for palliative treatment in the form of chemotherapy and/or radiotherapy and/or best supportive care. Patients disqualified from curative treatment were older (78 vs. 69 years, p < 0.02), had lower BMI values (24.5 vs. 25.7 kg/m2, p < 0.02), lower haemoglobin concentration (11.6 vs. 12.9 mg/l, p < 0.02), declared lower rate of nicotine abuse (50.5% vs. 72.1%, p < 0.02), and had a shorter time interval between first symptom and diagnosis (30 vs. 60 days, p = 0.02). As the majority of Polish patients with primary MIBC receive curative treatment, the stage of the disease alone seems not to be the leading cause of poor survival. However, appropriateness of qualification for RC and treatment quality needs to be assessed for final conclusion on the factors influencing outcomes of treatment in Poland.
波兰肌肉浸润性膀胱癌(MIBC)患者生存率低的一个潜在原因是,由于疾病晚期或表现不佳,患者最初无法接受根治性治疗。本研究的目的是描述新诊断的MIBC患者的护理模式。这是一项多中心回顾性队列研究,涉及296例连续的原发性组织学诊断为MIBC的患者。分析了治疗决定和潜在的临床因素。285例患者有完整的临床资料。164例(57.5%)患者适合根治性膀胱切除术(RC), 32例(11.2%)患者适合经尿道膀胱肿瘤切除术(TURBT)的第二步,随后进行全身化疗,4例(1.4%)患者在完全TURBT后仅适合辅助膀胱化疗,而其余85例(29.8%)患者适合姑息治疗,包括化疗和/或放疗和/或最佳支持治疗。不能获得根治性治疗的患者年龄较大(78 vs 69岁,p < 0.02), BMI值较低(24.5 vs. 25.7 kg/m2, p < 0.02),血红蛋白浓度较低(11.6 vs. 12.9 mg/l, p < 0.02),尼古丁滥用率较低(50.5% vs. 72.1%, p < 0.02),首次症状和诊断之间的时间间隔较短(30 vs. 60天,p = 0.02)。由于大多数波兰原发性MIBC患者接受了治愈性治疗,疾病的分期似乎不是导致生存率低的主要原因。然而,需要评估RC资格的适当性和治疗质量,以最终得出影响波兰治疗结果的因素的结论。